euro adhoc: Intercell AG
Personnel
Intercell appoints new Scientific
Advisory Board
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.
14.02.2006
Intercell AG announced today the appointment of its new Scientific Advisory Board (SAB). The company feels honored that the following academic scientists have accepted the invitation to serve in Intercell's new SAB: Rafi Ahmed (Emory University School of Medicine), Hubert Blum (University of Freiburg), Stanley N. Cohen (Stanford University), Franz Xaver Heinz (University of Vienna), Stefan H.E. Kaufmann (Max-Planck-Institute for Infection Biology), Staffan Normark (Karolinska Institute) and Hans Wigzell (Karolinska Institute).
Throughout Intercell's next growth stage, the new members will support the company with their broad knowledge and unique expertise in the fields of infectious diseases, microbiology, immunology and molecular biology as well as their worldwide networks. The new SAB will follow the original SAB that has been pivotal to launch the company eight years ago and that has accompanied Intercell on its way from a university spin-off to an internationally acknowledged vaccine player in the biotech arena.
The former SAB, chaired by Intercell's co-founder Max Birnstiel, included Hubert Blum, David Hirsh, Staffan Normark, Hamilton Smith, Hans Strander and Charles Weissmann. They have added much to Intercell's credibility, helped to implement high scientific standards and supported the company in finding its strategic focus. The new SAB will also give assistance to Intercell by offering the advice of outstanding scientists, with the company's primary focus on vaccines and immunotherapeutic treatments against infectious diseases.
Intercell's CSO, Alexander von Gabain, states: "I would like to thank the members of the founding SAB for their long-time commitment to our company and their outstanding contribution to create an excellent position in science and product development. I welcome the new SAB members who perfectly match the scientific profile that we need to develop the company into its next stage."
Max Birnstiel, co-founder and Chair of the founding SAB, states: "I am delighted that the new SAB members will continue our mission to support building excellence in biotech. Their competence, skills, and reputation is optimal for reaching Intercell's strategic goal to fight infectious diseases and also to achieving state of the art vaccine technologies."
This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
end of announcement euro adhoc 14.02.2006 07:11:00
Further inquiry note:
Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com
Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market